Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer's Disease

NCT06297590 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06297590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06297590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Recruiting
Start date
August 15, 2024
Completion date
February 28, 2027
Enrollment
48 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease